120 related articles for article (PubMed ID: 16382294)
1. Vasopeptidase inhibition peri- and post-MI in Zucker insulin resistant rats: effect on MI size, arrhythmias, remodeling, function and fetal gene expression.
Lapointe N; Nguyen QT; Desjardins JF; Tsoporis J; Marcotte F; Pourdjabbar A; Parker TG; Moe G; Adam A; Rouleau JL
Cardiovasc Drugs Ther; 2005 Oct; 19(5):323-32. PubMed ID: 16382294
[TBL] [Abstract][Full Text] [Related]
2. Effects of the vasopeptidase inhibitor omapatrilat on peri- and postmyocardial infarction in Zucker lean rats.
Lapointe N; Parker TG; Tsoporis JN; Nguyen QT; Marcotte F; Adam A; Lou I; Rouleau JL
Can J Cardiol; 2005 Mar; 21(3):291-7. PubMed ID: 15776120
[TBL] [Abstract][Full Text] [Related]
3. Effects of pre-, peri-, and postmyocardial infarction treatment with omapatrilat in rats: survival, arrhythmias, ventricular function, and remodeling.
Lapointe N; Nguyen QT; Desjardins JF; Marcotte F; Pourdjabbar A; Moe G; Calderone A; Rouleau JL
Am J Physiol Heart Circ Physiol; 2003 Jul; 285(1):H398-405. PubMed ID: 12663265
[TBL] [Abstract][Full Text] [Related]
4. Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
Blais C; Lapointe N; Rouleau JL; Clément R; Bachvarov DR; Adam A
Can J Physiol Pharmacol; 2002 Jan; 80(1):48-58. PubMed ID: 11911226
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
Lapointe N; Blais C; Adam A; Parker T; Sirois MG; Gosselin H; Clément R; Rouleau JL
J Am Coll Cardiol; 2002 May; 39(10):1692-8. PubMed ID: 12020499
[TBL] [Abstract][Full Text] [Related]
6. Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival.
Pourdjabbar A; Parker TG; Desjardins JF; Nguyen QT; Tsoporis JN; Lapointe N; Rouleau JL
Can J Physiol Pharmacol; 2005 Nov; 83(11):989-98. PubMed ID: 16391707
[TBL] [Abstract][Full Text] [Related]
7. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
Blais C; Lapointe N; Rouleau JL; Clément R; Gervais N; Geadah D; Adam A
Peptides; 2001 Jun; 22(6):953-62. PubMed ID: 11390026
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of a vasopeptidase inhibitor vs. an angiotensin converting enzyme inhibitor on cardiomyocyte apoptosis in rats with heart failure.
Lapointe N; Tsoporis JN; Parker TG; Blais C; Adam A; Rouleau D; Slaughter G; Clément R; Deschepper CE; Rouleau JL
Mol Cell Biochem; 2003 Dec; 254(1-2):235-45. PubMed ID: 14674703
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
10. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.
Pourdjabbar A; Parker TG; Nguyen QT; Desjardins JF; Lapointe N; Tsoporis JN; Rouleau JL
Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1997-2005. PubMed ID: 15539424
[TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction.
Holzgrefe HH; Arthur SR; Powell JR
Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):696-703. PubMed ID: 12100002
[TBL] [Abstract][Full Text] [Related]
12. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.
Kompa AR; See F; Lewis DA; Adrahtas A; Cantwell DM; Wang BH; Krum H
J Pharmacol Exp Ther; 2008 Jun; 325(3):741-50. PubMed ID: 18334667
[TBL] [Abstract][Full Text] [Related]
13. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
[TBL] [Abstract][Full Text] [Related]
14. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.
Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM
J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120
[TBL] [Abstract][Full Text] [Related]
15. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
[TBL] [Abstract][Full Text] [Related]
16. Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism.
Ebrahim Z; Baxter GF; Yellon DM
Cardiovasc Drugs Ther; 2004 Mar; 18(2):127-34. PubMed ID: 15162074
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Maniu CV; Meyer DM; Redfield MM
Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
[TBL] [Abstract][Full Text] [Related]
18. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion.
Rajani SF; Imani A; Faghihi M; Izad M; Kardar GA; Salehi Z
Eur J Pharmacol; 2019 Mar; 847():61-71. PubMed ID: 30684466
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
Loch D; Hoey A; Brown L
Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
[TBL] [Abstract][Full Text] [Related]
20. Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure.
Cha YM; Redfield MM; Shah S; Shen WK; Fishbein MC; Chen PS
Heart Rhythm; 2005 Sep; 2(9):984-90. PubMed ID: 16171755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
